vs
AMERICAN SHARED HOSPITAL SERVICES（AMS）与林德（LIN）财务数据对比。点击上方公司名可切换其他公司
林德的季度营收约是AMERICAN SHARED HOSPITAL SERVICES的1.1倍（$8.8M vs $7.7M），林德同比增速更快（8.2% vs -14.8%），林德自由现金流更多（$898.0K vs $-2.7M），过去两年AMERICAN SHARED HOSPITAL SERVICES的营收复合增速更高（21.7% vs -96.7%）
美国共享医院服务公司为医疗机构提供放射治疗、立体定向放射外科及诊断成像设备的整体外包解决方案，免除医院高昂的前期资本投入，主要业务覆盖北美，同时服务拉美及部分亚太地区的公立、私立医院客户。
林德是全球知名跨国化工企业，按市场份额及营收计为全球最大工业气体供应商。公司1879年由德国科学家、工程师卡尔·冯·林德在德国威斯巴登创立，现总部位于英国沃金，在爱尔兰注册，2018年由原林德股份公司与1907年在美国成立的普莱克斯合并组建。
AMS vs LIN — 直观对比
营收规模更大
LIN
是对方的1.1倍
$7.7M
营收增速更快
LIN
高出23.0%
-14.8%
自由现金流更多
LIN
多$3.6M
$-2.7M
两年增速更快
AMS
近两年复合增速
-96.7%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $7.7M | $8.8M |
| 净利润 | $-631.0K | — |
| 毛利率 | 11.7% | 48.5% |
| 营业利润率 | -18.1% | 27.8% |
| 净利率 | -8.2% | — |
| 营收同比 | -14.8% | 8.2% |
| 净利润同比 | 52.5% | — |
| 每股收益（稀释后） | $-0.09 | $3.98 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMSLIN
| Q1 26 | — | $8.8M | ||
| Q4 25 | $7.7M | $8.8B | ||
| Q3 25 | $7.2M | $8.6B | ||
| Q2 25 | $7.1M | $8.5B | ||
| Q1 25 | $6.1M | $8.1B | ||
| Q4 24 | $9.1M | $8.3B | ||
| Q3 24 | $7.0M | $8.4B | ||
| Q2 24 | $7.1M | $8.3B |
净利润AMSLIN
| Q1 26 | — | — | ||
| Q4 25 | $-631.0K | $1.5B | ||
| Q3 25 | $-17.0K | $1.9B | ||
| Q2 25 | $-280.0K | $1.8B | ||
| Q1 25 | $-625.0K | $1.7B | ||
| Q4 24 | $-1.3M | $1.7B | ||
| Q3 24 | $-207.0K | $1.6B | ||
| Q2 24 | $3.6M | $1.7B |
毛利率AMSLIN
| Q1 26 | — | 48.5% | ||
| Q4 25 | 11.7% | — | ||
| Q3 25 | 22.1% | — | ||
| Q2 25 | 23.1% | — | ||
| Q1 25 | 15.4% | — | ||
| Q4 24 | 35.3% | — | ||
| Q3 24 | 19.6% | — | ||
| Q2 24 | 35.0% | — |
营业利润率AMSLIN
| Q1 26 | — | 27.8% | ||
| Q4 25 | -18.1% | 23.0% | ||
| Q3 25 | -4.8% | 27.5% | ||
| Q2 25 | -7.7% | 27.7% | ||
| Q1 25 | -21.3% | 26.9% | ||
| Q4 24 | -20.2% | 27.4% | ||
| Q3 24 | -12.7% | 25.0% | ||
| Q2 24 | -0.0% | 26.4% |
净利率AMSLIN
| Q1 26 | — | — | ||
| Q4 25 | -8.2% | 17.5% | ||
| Q3 25 | -0.2% | 22.4% | ||
| Q2 25 | -4.0% | 20.8% | ||
| Q1 25 | -10.2% | 20.6% | ||
| Q4 24 | -14.6% | 20.8% | ||
| Q3 24 | -3.0% | 18.5% | ||
| Q2 24 | 51.0% | 20.1% |
每股收益（稀释后）AMSLIN
| Q1 26 | — | $3.98 | ||
| Q4 25 | $-0.09 | $3.28 | ||
| Q3 25 | $0.00 | $4.09 | ||
| Q2 25 | $-0.04 | $3.73 | ||
| Q1 25 | $-0.10 | $3.51 | ||
| Q4 24 | $-0.21 | $3.61 | ||
| Q3 24 | $-0.03 | $3.22 | ||
| Q2 24 | $0.55 | $3.44 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.5M | $4.0M |
| 总债务越低越好 | $17.4M | $24.7M |
| 股东权益账面价值 | $24.0M | $40.1M |
| 总资产 | $55.5M | $86.3M |
| 负债/权益比越低杠杆越低 | 0.72× | 0.62× |
8季度趋势，按日历期对齐
现金及短期投资AMSLIN
| Q1 26 | — | $4.0M | ||
| Q4 25 | $3.5M | $5.1B | ||
| Q3 25 | $5.1M | $4.5B | ||
| Q2 25 | $11.1M | $4.8B | ||
| Q1 25 | $11.2M | $5.3B | ||
| Q4 24 | $11.0M | $4.8B | ||
| Q3 24 | $13.8M | $5.2B | ||
| Q2 24 | $14.2M | $4.6B |
总债务AMSLIN
| Q1 26 | — | $24.7M | ||
| Q4 25 | $17.4M | $20.7B | ||
| Q3 25 | $18.2M | $18.6B | ||
| Q2 25 | $19.1M | $19.7B | ||
| Q1 25 | $19.9M | $17.6B | ||
| Q4 24 | $20.4M | $15.3B | ||
| Q3 24 | $14.4M | $17.5B | ||
| Q2 24 | $15.1M | $16.9B |
股东权益AMSLIN
| Q1 26 | — | $40.1M | ||
| Q4 25 | $24.0M | $38.2B | ||
| Q3 25 | $24.6M | $38.6B | ||
| Q2 25 | $24.5M | $38.5B | ||
| Q1 25 | $24.6M | $38.0B | ||
| Q4 24 | $25.2M | $38.1B | ||
| Q3 24 | $26.4M | $39.2B | ||
| Q2 24 | $26.5M | $38.2B |
总资产AMSLIN
| Q1 26 | — | $86.3M | ||
| Q4 25 | $55.5M | $86.8B | ||
| Q3 25 | $59.6M | $86.0B | ||
| Q2 25 | $63.5M | $86.1B | ||
| Q1 25 | $63.3M | $82.7B | ||
| Q4 24 | $60.2M | $80.1B | ||
| Q3 24 | $63.3M | $82.5B | ||
| Q2 24 | $60.8M | $80.2B |
负债/权益比AMSLIN
| Q1 26 | — | 0.62× | ||
| Q4 25 | 0.72× | 0.54× | ||
| Q3 25 | 0.74× | 0.48× | ||
| Q2 25 | 0.78× | 0.51× | ||
| Q1 25 | 0.81× | 0.46× | ||
| Q4 24 | 0.81× | 0.40× | ||
| Q3 24 | 0.54× | 0.45× | ||
| Q2 24 | 0.57× | 0.44× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-704.0K | — |
| 自由现金流经营现金流 - 资本支出 | $-2.7M | $898.0K |
| 自由现金流率自由现金流/营收 | -34.8% | 10.2% |
| 资本支出强度资本支出/营收 | 25.7% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-8.5M | $4.2B |
8季度趋势，按日历期对齐
经营现金流AMSLIN
| Q1 26 | — | — | ||
| Q4 25 | $-704.0K | $3.0B | ||
| Q3 25 | $1.7M | $2.9B | ||
| Q2 25 | $-372.0K | $2.2B | ||
| Q1 25 | $2.5M | $2.2B | ||
| Q4 24 | $274.0K | $2.8B | ||
| Q3 24 | $472.0K | $2.7B | ||
| Q2 24 | $1.3M | $1.9B |
自由现金流AMSLIN
| Q1 26 | — | $898.0K | ||
| Q4 25 | $-2.7M | $1.6B | ||
| Q3 25 | $-2.0M | $1.7B | ||
| Q2 25 | $-2.3M | $954.0M | ||
| Q1 25 | $-1.5M | $891.0M | ||
| Q4 24 | $-4.4M | $1.6B | ||
| Q3 24 | $-407.0K | $1.7B | ||
| Q2 24 | $70.0K | $796.0M |
自由现金流率AMSLIN
| Q1 26 | — | 10.2% | ||
| Q4 25 | -34.8% | 17.9% | ||
| Q3 25 | -28.3% | 19.4% | ||
| Q2 25 | -32.1% | 11.2% | ||
| Q1 25 | -24.7% | 11.0% | ||
| Q4 24 | -48.4% | 18.8% | ||
| Q3 24 | -5.8% | 19.9% | ||
| Q2 24 | 1.0% | 9.6% |
资本支出强度AMSLIN
| Q1 26 | — | — | ||
| Q4 25 | 25.7% | 16.6% | ||
| Q3 25 | 51.6% | 14.8% | ||
| Q2 25 | 26.9% | 14.8% | ||
| Q1 25 | 65.7% | 15.7% | ||
| Q4 24 | 51.4% | 15.1% | ||
| Q3 24 | 12.6% | 12.8% | ||
| Q2 24 | 17.2% | 13.7% |
现金转化率AMSLIN
| Q1 26 | — | — | ||
| Q4 25 | — | 1.98× | ||
| Q3 25 | — | 1.53× | ||
| Q2 25 | — | 1.25× | ||
| Q1 25 | — | 1.29× | ||
| Q4 24 | — | 1.63× | ||
| Q3 24 | — | 1.76× | ||
| Q2 24 | 0.36× | 1.16× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMS
| Direct Patient Services | $4.0M | 51% |
| Rental Income From Medical Services | $2.7M | 35% |
| Pbrt Services | $1.2M | 15% |
LIN
暂无分部数据
